<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832854</url>
  </required_header>
  <id_info>
    <org_study_id>GO42501</org_study_id>
    <secondary_id>2020-002853-11</secondary_id>
    <nct_id>NCT04832854</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab&#xD;
      alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for&#xD;
      participants with previously untreated locally advanced non-small cell lung cancer (NSCLC).&#xD;
      The study will also evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of&#xD;
      atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as&#xD;
      neoadjuvant treatment, followed by adjuvant atezolizumab plus tiragolumab or adjuvant&#xD;
      platinum-based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Surgical Delays</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Operative and Post-operative Complications</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Surgical Cancellations Related to Study Treatment</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve Major Pathological Response (MPR)</measure>
    <time_frame>At the time of surgery (approximately Weeks 17-20)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pathological Complete Response (pCR)</measure>
    <time_frame>At the time of surgery (approximately Weeks 17-20)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>From baseline to disease progression that precludes surgical resection, or local or distant disease recurrence after surgery, or death from any cause (up to approximately 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Atezolizumab</measure>
    <time_frame>Day 1 of Cycle 1 (cycle=21 days): pre-dose and 30 minutes (min) post-dose; Day 1 of Cycles 2, 3, 4, 5, 8, 12, 16: pre-dose; at treatment discontinuation (TD) visit (up to approximately 9 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Tiragolumab</measure>
    <time_frame>Day 1 of Cycle 1 (cycle=21 days): pre-dose and 30 min post-dose; Day 1 of Cycles 2, 3, 4, 5, 8, 12, 16: pre-dose; at TD visit (up to approximately 9 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab</measure>
    <time_frame>Prior to the first infusion on Day 1 of Cycles 1, 2, 3, 4, 5, 8, 12 and 16 (cycle=21 days) and at TD visit (up to approximately 9 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ADAs to Tiragolumab</measure>
    <time_frame>Prior to the first infusion on Day 1 of Cycles 1, 2, 3, 4, 5, 8, 12 and 16 (cycle=21 days) and at TD visit (up to approximately 9 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Non-Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with high programmed death-ligand 1 (PD-L1) expression level will be enrolled in Cohort A and receive neoadjuvant atezolizumab plus tiragolumab for 4 cycles, followed by surgical resection and either adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles at the discretion of the investigator.&#xD;
Chemotherapy may include:&#xD;
cisplatin/carboplatin + pemetrexed (for non-squamous only)&#xD;
cisplatin/carboplatin + gemcitabine (for squamous only)&#xD;
carboplatin + paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All comers, which are participants with any PD-L1 expression level, will be enrolled in Cohort B and receive neoadjuvant atezolizumab plus tiragolumab plus chemotherapy for 4 cycles, followed by surgical resection and adjuvant atezolizumab plus tiragolumab for 16 cycles.&#xD;
Chemotherapy may include:&#xD;
cisplatin/carboplatin + pemetrexed (for non-squamous only)&#xD;
cisplatin/carboplatin + gemcitabine (for squamous only)&#xD;
carboplatin + paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
    <other_name>MTIG7192A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin at 75 mg/m^2 will be administered by IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed at 500 mg/m^2 will be administered by IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine at 1000 or 1250 mg/m^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.</description>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel at 175 or 200 mg/m^2 will be administered by IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Cohort A (PD-L1 High)</arm_group_label>
    <arm_group_label>Cohort B (PD-L1 All Comers)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only)&#xD;
             NSCLC of squamous or non-squamous histology&#xD;
&#xD;
          -  Eligible for R0 resection with curative intent at the time of screening&#xD;
&#xD;
          -  Adequate pulmonary function to be eligible for surgical resection with curative intent&#xD;
&#xD;
          -  Eligible to receive a platinum-based chemotherapy regimen&#xD;
&#xD;
          -  Measurable disease, as assessed by the investigator per Response Evaluation Criteria&#xD;
             in Solid Tumors (RECIST) v1.1&#xD;
&#xD;
          -  Availability of a representative tumor specimen that is suitable for determination of&#xD;
             PD-L1 status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Normal life expectancy, excluding lung cancer mortality risk&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Negative human immunodeficiency virus (HIV) test at screening&#xD;
&#xD;
          -  Negative serology for active hepatitis B virus (HBV) and active hepatitis C virus&#xD;
             (HCV) at screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or&#xD;
             NSCLC not otherwise specified&#xD;
&#xD;
          -  Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC&#xD;
&#xD;
          -  Any prior therapy for lung cancer&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest computed tomography (CT) scan&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  NSCLC with an activating EGFR mutation or ALK fusion oncogene&#xD;
&#xD;
          -  Known c-ros oncogene 1 (ROS1) rearrangement&#xD;
&#xD;
          -  History of malignancy other than NSCLC within 5 years prior to screening, with the&#xD;
             exception of malignancies with negligible risk of metastasis or death&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment or any active&#xD;
             infection that, in the opinion of the investigator, could impact patient safety&#xD;
&#xD;
          -  Prior treatment with CD127 agonists or immune checkpoint blockade therapies, including&#xD;
             anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medication&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO42501 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Cancer Center; Division of Medical Oncology &amp; Experimental Therapeutics</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown U; Lombardi Comp Can</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016-1468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winthrop Univ Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli; Servicio de Oncologia</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia</name>
      <address>
        <city>A Coruña</city>
        <state>LA Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro; Servicio de Oncologia</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel; Onkologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen; Onkologie/Hämatologie</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

